Karyopharm Therapeutics Inc. (KPTI) by event type
KPTI moves most on analyst downgrades — a median of +2.92% at 30 minutes across 13 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the KPTI overview →
How KPTI reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades 8 of 2,603 | 13 | +2.92% | 62% | -0.71% |
| Rating reiterations 2,987 of 3,522 | 53 | -0.23% | 49% | -1.56% |
| Price-target cuts 9 of 1,527 | 13 | +1.02% | 54% | -2.80% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how KPTI usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst downgrades → · Rating reiterations → · Price-target cuts → · KPTI overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc. (ACAD) | 392 | -0.14% | 43% |
| BioXcel Therapeutics, Inc. (BTAI) | 392 | -0.75% | 41% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 391 | +0.13% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.